Navigation Links
Genomic Health Announces Study Establishing the Utility of Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated with Aromatase Inhibitors
Date:12/13/2008

SAN ANTONIO, Dec. 13 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced findings from a European study demonstrating that the Oncotype DX Recurrence Score(R) result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive breast cancer patients who are treated with the aromatase inhibitor anastrozole or with tamoxifen. Researchers from the Royal Marsden Hospital in London discussed results today in an oral presentation at the 31st Annual San Antonio Breast Cancer Symposium.

Oncotype DX is a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early stage breast cancer. In this prospectively- designed study, researchers used Oncotype DX to analyze tumor samples from 1,231 patients in the ATAC (Arimidex(R), Tamoxifen, Alone or in Combination) trial, a landmark study that established the wide use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer.

"Our multivariate analysis confirms that along with other standard measures such as tumor size, Oncotype DX contributes independently to providing a more complete picture of prognosis," said Mitch Dowsett, Ph.D., Royal Marsden Hospital and Team Leader at the Breakthrough Breast Cancer Research Centre in London. "Physicians can take this information into account when making chemotherapy treatment decisions for both node-negative and node- positive early stage breast cancer patients planned for either anastrozole or tamoxifen treatment."

The study assessed 9-year distant recurrence for women in the anastrozole and tamoxifen monotherapy arms of the ATAC trial, including patients with disease that h
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...009) Wistar Institute researchers and collaborato...k University have identified immune system markers...rs in people at high risk for developing lung canc...Cancer Research , a journal of the American Associ...blood test to detect lung cancer in its earliest p...
(Date:12/1/2009)...MITHFIELD, R.I., Dec. 1 In the wo...ons are hazardous and can result in injury -- or w...on, a handful of persistent bad assumptions are wi... occupational Hearing Conservation Programs (HCPs...paper from Howard Leight, " Bad Assumptions abo...
(Date:12/1/2009)... Abrazo Media Relations-- The Cent...:// www.pedsorthopaedics.com ) located in Mesa, Ar...n Dr. J. Hunt Udall to its practice. ,, Dr. Ud...surgery after recently completing his fellowship t...etts where he focused on adult and pediatric ortho...
(Date:12/1/2009)...appiness declines with age are more likely to enga...g. Their misguided negative view of the aging proc... and encourage them to make the most of the presen...indings 1 by Dr. John Garry and Dr. Maria Lohan f...are published online in Springer,s Journal of Hap...
(Date:12/1/2009)...nsion announces general availability of its new En...d-to-end endpoint management capabilities on a sin...sole architecture. , Scot...a global leader in endpoint management and securit... Management and Security Suite (LEMSS) that will...
Breaking Medicine News(10 mins):Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 3Health News:New White Paper Details Six Common Bad Assumptions About Hearing Protection 2Health News:New White Paper Details Six Common Bad Assumptions About Hearing Protection 3Health News:Orthopaedic Surgeon Dr. J. Hunt Udall Joins the Center for Pediatric Orthopaedics and Scoliosis as One of Few Trained Doctors to Perform Minimally Invasive Hip Arthroscopy 2Health News:Binge drinking youths find getting old a drag 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 3Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 4Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 5Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 6
... survival for elderly patients with lung cancer ha...care expenditures for lung cancer treatment. The s...ute, and National Bureau of Economic Research rese... rose by less than one month between 1983 and 1997...
...odel of nonprofit fund-raising events and raises ... PHILADELPHIA, Oct. 20 Men and women from,across ...ked 10 miles,throughout Philadelphia today in the ...rts of the American Diabetes,Association. (Photo:...
...r Research, LLC, a pioneer in,the field of Busines...s,first-ever study on the Indian Contract Research...ort titled ,Indian Contract Research Industry, (CR...dia currently stands as one of the highest ranked ...
...ker Nancy Pelosi,issued the following statement to... Stark on the House floor during debate on the Sta...ay,s debate in the House to override the President...hat,Congressman Stark said during the debate was i...
... Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced t...pplement to a shelf registration statement with th... proposed public offering of,10,000,000 shares of ...shares of common stock to cover over-allotments, i...
...r-spurring gene goes to work, researchers say , F... they,ve identified a protein that could play a ke...According to a team at the Kimmel Cancer Center at...as. , However, pp32 is absent in the most aggressi...
Other Medicine News:Health News:Spending more for lung cancer treatment did not substantially increase patients' lives 2Health News:American Diabetes Association Steps Up to Fight Diabetes 2Health News:American Diabetes Association Steps Up to Fight Diabetes 3Health News:EmPower Research Launches Indian CRO Industry Report 2Health News:Arena Pharmaceuticals Announces Public Offering of Common Stock 2Health News:Protein Gives Clues to Pancreatic Cancer 2
(Date:12/1/2009)... CHENGDU, China, Dec. 1 /PRNewswire-Asia-First...mex: TPI ), a manufacturer and supplier of,modern... Chengdu, China, today,announced that it has recei...,Administration (SFDA) to produce Pediatric Fever ... (SFDA approval number Z20093060) and Antibacteria...
(Date:12/1/2009)...VILLE, Md., Dec. 1 Vanda...oday that the waiting period has expired under the...t of 1976 with respect to Vanda,s agreement, dated...at the agreement is now effective. Expiration of ...s of the agreement, triggers an upfront payment to...
(Date:12/1/2009)...DA, Md., Dec. 1 Micromet...ny developing novel, proprietary antibodies for th... diseases today announced that Bayer Schering Phar...ollaboration and license agreement entered into on...or the treatment of solid tumors. ,, Under the ...
Breaking Medicine Technology:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 3Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 2Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 3Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 4Sensing disasters from space 10483 1Sensing disasters from space 10483 2General anesthetics lead to learning disabilities in animal models 59954 1General anesthetics lead to learning disabilities in animal models 59954 2General anesthetics lead to learning disabilities in animal models 59954 3Flu shots not to be sneezed at 59952 1Flu shots not to be sneezed at 59952 2
...aboratory,s Technology Transfer Expertise to Suppo...K, March 30 Biomarkers have become increasingly i...od for risk assessment, early detection, testing n...better drugs once they are developed. As part of ... for Alzheimer,s and other diseases, BARC Central ...
...as now been studied in combination with the most c...10 mg, 20 mg) in patients with mixed dyslipidemia ...y showed that Abbott ,s TRILIPIX(R) (fenofibric a...rosuvastatin calcium met all of the study,s primar...rosuvastatin calcium 5 mg significantly improved H...
Other Medicine Technology:BARC Central Laboratory Joins Alzheimer's Association Research Roundtable 2BARC Central Laboratory Joins Alzheimer's Association Research Roundtable 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5
...the pathologist to visualize the presence of Human...g on a choice of sample types: tissue, monolayer-b... HPV cocktails utilize proprietary probe formulati...to HPV genotypes 16, 18, 31, 33, 35, 39, 51, 52, 5...
Afinion AS100 Analyzer
ID - Candida albicans
AlbiQuick™
Medicine Products: